phase trial monoclonal antibody acute myelogenous leukemia specific bone marrow internalization radionuclide patients myeloid leukemias phase trial doses mouse monoclonal antibody mAb reactive glycoprotein myeloid leukemia blasts early hematopoietic progenitor cells normal stem cells trace-labeled detailed pharmacokinetic dosimetric studies serial sampling blood bone marrow whole-body gamma-camera imaging Total mg immediate adverse effects Absorption targets vivo biopsy pharmacology flow cytometry saturation available sites doses equal entire bone marrow hours injection optimal imaging dose Bone marrow biopsies significant dose-related uptake hour infusion patients majority dose marrow Tumor regressions estimated rad/mCi whole body rad/mCi plasma rad/mCi red marrow compartment majority bound immunoglobulin IgG target cells vivo data whole bone marrow ablative doses rapid specific quantitative delivery bone marrow efficient internalization target cells vivo delivery isotopes auger alpha emitters toxins important molecules leukemia cells normal hematopoietic progenitor cells feasible 